OS
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mohamad Mohty, Gerard Socié, Jeff Szer, Dietger Niederwieser, Jason Butler, Eva Wagner-Drouet, Reuven Or, Tsila Rovenvald-Zuckerman, Sinem Civriz Bozdag, Edouard Forcade, Giovanni Grillo, Nicolaus Kröger, Friedrich Stölzel, Domenico Russo, Jaime Sanz, Rajendra Sarkar, Tommaso Stefanelli, Celine Wilke, Robert Zeiser, Nikolas von Bubnoff
J Clin Oncol 43(34) 3639-3645
Approximately 30%-50% of patients develop acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (Allo-HCT), representing a major limitation of this treatment. Although corticosteroids remain the standard first-line therapy for aGVHD, up to 50% of patients become steroid-refractory (SR). REACH2 is a phase III study of ruxolitinib versus best available therapy (BAT) in patients age 12 years and older with SR-aGVHD after Allo-HCT. We present the final efficacy and safety outcomes from REACH2 after 24 months of treatment. Cumulative median (range) duration of response was 167 (22-677) days with ruxolitinib and 106 (10-526) days with BAT. Median overall survival and event-free survival were 10.7 and 8.3 months for ruxolitinib, compared with 5.8 and 4.2 months, respectively, with BAT. Median failure-free survival was significantly longer with ruxolitinib than with BAT (4.86 v 1.02 months, P < .001). Similar numbers of nonrelapse mortality events were observed with ruxolitinib and BAT (72 v 71), and malignancy relapse/progression events remained low across both groups. Numerically higher chronic GVHD rates were noted with ruxolitinib than with BAT from 12 months; however, 95% confidence intervals overlapped. Safety observations were consistent with the primary analysis results. Ruxolitinib provided efficacy advantages over BAT in patients with SR-aGVHD over 24 months.
1 个 Figure · 3 个 KM 面板
FIG 2. Efficacy outcomes (full analysis set). Kaplan-Meier curves for ruxolitinib and BAT for (A) OS, (B) EFS, and (C) FFS. OS was defined as the time from date of random assignment to the date of death due to any cause. EFS was defined as the time from date of random assignment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. FFS was defined as the time from the date of random assignment to the date of hematologic disease relapse/progression, nonrelapse mortality, or addition of new systemic aGVHD treatment. aGVHD, acute graft-versus-host disease; BAT, best available therapy; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; KM, Kaplan-Meier, N, number of patients in a group; n, number of patients with a response; OS, overall survival.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel B
Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。